Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Salicylic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.78 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.78 |
| ▸ | HPGD | P15428 | 7/20 | 0.78 |
| ▸ | CA1 | P00915 | 2/20 | 0.78 |
| ▸ | CA9 | Q16790 | 2/20 | 0.78 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.78 |
| ▸ | CA12 | O43570 | 1/20 | 0.78 |
| ▸ | CA2 | P00918 | 1/20 | 0.78 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.78 |
| ▸ | CA4 | P22748 | 1/20 | 0.78 |
| ▸ | CA6 | P23280 | 1/20 | 0.78 |
| ▸ | CA7 | P43166 | 1/20 | 0.78 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.78 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.78 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.61 |
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | TSHR | P16473 | 2/20 | 0.61 |
| ▸ | CASP7 | P55210 | 2/20 | 0.55 |
| ▸ | G6PD | P11413 | 1/20 | 0.55 |
| ▸ | CASP6 | P55212 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Salicylic Acid SCHEMBL1810677 | 0.91 | ALDH1A1 (0.86) | ALDH1A1KDM4EHPGDCA1CA9 | |
| Salicylic Acid SCHEMBL1193531 | 0.91 | ALDH1A1 (0.86) | ALDH1A1KDM4EHPGDCA1CA9 | |
| Salicylic Acid SCHEMBL28189123 | 0.89 | ALDH1A1 (0.82) | ALDH1A1KDM4EHPGDCA1CA9 | |
| Salicylic Acid SCHEMBL29110644 | 0.89 | ALDH1A1 (0.90) | ALDH1A1KDM4EHPGDCA1CA9 | |
| Salicylic Acid SCHEMBL27499117 | 0.89 | ALDH1A1 (0.90) | ALDH1A1KDM4EHPGDCA1CA9 | |
| Salicylic Acid SCHEMBL8433746 | 0.89 | ALDH1A1 (1.00) | ALDH1A1KDM4EHPGDCA1CA9 | |
| Salicylic Acid SCHEMBL29362663 | 0.89 | ALDH1A1 (1.00) | ALDH1A1KDM4EHPGDCA1CA9 | |
| Salicylic Acid SCHEMBL1967 | 0.89 | ALDH1A1 (1.00) | ALDH1A1KDM4EHPGDCA1CA9 | |
| Salicylic Acid SCHEMBL1509155 | 0.89 | ALDH1A1 (1.00) | ALDH1A1KDM4EHPGDCA1CA9 | |
| Salicylic Acid SCHEMBL29360246 | 0.89 | ALDH1A1 (1.00) | ALDH1A1KDM4EHPGDCA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090004128-A1 | Non-Irritant Rapid-Action Dipilatory Composition | PRODUCCIONES INFOVISION (MX) | 2009-01-01 | — | — | US | claimed |
| US-12491493-B1 | Amine appended bimetallic metal-organic framework (MOF-74) for carbon dioxide capture and method of preparation thereof | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2025-12-09 | — | — | US | disclosed |
| EP-4088784-A1 | COMPOSITION FOR DISINFECTION AND COSMETIC APPLICATIONS | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2022-11-16 | — | — | EP | disclosed |
| US-9150504-B2 | Fatty acid guanidine and salicylate guanidine derivatives and their uses | CATABASIS PHARMACEUTICALS, INC. (US) | 2015-10-06 | — | — | US | disclosed |
| US-9150504-B2 | Fatty acid guanidine and salicylate guanidine derivatives and their uses | CATABASIS PHARMACEUTICALS, INC. (US) | 2015-10-06 | — | — | US | disclosed |
| US-9150504-B2 | Fatty acid guanidine and salicylate guanidine derivatives and their uses | CATABASIS PHARMACEUTICALS, INC. (US) | 2015-10-06 | — | — | US | disclosed |
| EP-2701509-A4 | FATTY ACID GUANIDINE AND SALICYLATE GUANIDINE DERIVATIVES AND THEIR USES | CATABASIS PHARMACEUTICALS INC (US) | 2015-06-17 | — | — | EP | disclosed |
| CN-104262204-A | Preparation method of guanidine salicylate compound | JIANGSU TIANSHENG PHARMACEUTICAL CO LTD | 2015-01-07 | — | — | CN | disclosed |
| CN-104262204-A | Preparation method of guanidine salicylate compound | JIANGSU TIANSHENG PHARMACEUTICAL CO LTD | 2015-01-07 | — | — | CN | disclosed |
| EP-2701509-A1 | FATTY ACID GUANIDINE AND SALICYLATE GUANIDINE DERIVATIVES AND THEIR USES | Catabasis Pharmaceuticals, Inc. (US) | 2014-03-05 | — | — | EP | disclosed |
| EP-2701509-A1 | FATTY ACID GUANIDINE AND SALICYLATE GUANIDINE DERIVATIVES AND THEIR USES | Catabasis Pharmaceuticals, Inc. (US) | 2014-03-05 | — | — | EP | disclosed |
| EP-2701509-A1 | FATTY ACID GUANIDINE AND SALICYLATE GUANIDINE DERIVATIVES AND THEIR USES | Catabasis Pharmaceuticals, Inc. (US) | 2014-03-05 | — | — | EP | disclosed |
| WO-2012149352-A1 | FATTY ACID GUANIDINE AND SALICYLATE GUANIDINE DERIVATIVES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2012-11-01 | — | — | WO | disclosed |
| WO-2012149352-A1 | FATTY ACID GUANIDINE AND SALICYLATE GUANIDINE DERIVATIVES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2012-11-01 | — | — | WO | disclosed |
| WO-2012149352-A1 | FATTY ACID GUANIDINE AND SALICYLATE GUANIDINE DERIVATIVES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2012-11-01 | — | — | WO | disclosed |
| US-20120277305-A1 | FATTY ACID GUANIDINE AND SALICYLATE GUANIDINE DERIVATIVES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2012-11-01 | — | — | US | disclosed |
| US-20120277305-A1 | FATTY ACID GUANIDINE AND SALICYLATE GUANIDINE DERIVATIVES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2012-11-01 | — | — | US | disclosed |
| US-20120277305-A1 | FATTY ACID GUANIDINE AND SALICYLATE GUANIDINE DERIVATIVES AND THEIR USES | CATABASIS PHARMACEUTICALS, INC. (US) | 2012-11-01 | — | — | US | disclosed |
| US-20090004128-A1 | Non-Irritant Rapid-Action Dipilatory Composition | PRODUCCIONES INFOVISION (MX) | 2009-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120277305-A1 | FATTY ACID GUANIDINE AND SALICYLATE GUANIDINE DERIVATIVES AND THEIR USES | SCD, SCD5, FASN | ALDH1A1 385/4885KDM4E 2337/4885HPGD 612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.